JNJ-78934804
Sponsors
Janssen - Cilag International, Janssen Research & Development, LLC
Conditions
Colitis, UlcerativeCrohn DiseaseCrohn's DiseaseModerately to Severely Active Crohn's DiseaseModerately to Severely Active Ulcerative Colitis
Phase 2
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
Active, not recruitingNCT05242471
Start: 2022-07-22End: 2029-11-05Updated: 2026-05-08
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Active, not recruitingNCT05242484
Start: 2022-09-19End: 2029-03-27Updated: 2026-05-15
A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis
Active, not recruitingCTIS2023-504743-13-00
Start: 2022-11-30Target: 383Updated: 2026-01-26
A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn’s Disease
Active, not recruitingCTIS2023-504741-32-00
Start: 2022-11-30Target: 433Updated: 2026-01-19
Phase 3
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Not yet recruitingNCT07577843
Start: 2026-05-29End: 2030-07-12Target: 460Updated: 2026-05-11
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
Not yet recruitingNCT07577856
Start: 2026-05-29End: 2030-10-30Target: 644Updated: 2026-05-11